「control」の検索結果

Generate forest plots for meta-analysis of continuous data. Input a CSV file containing study names, means, standard deviations, and sample sizes for experimental and control groups. Output forest plot PNG and data table CSV.

日本語の概要は準備中です。原文の説明を表示しています。

Process CRISPR screening data to identify essential genes and hit candidates. Performs quality control, statistical analysis (RRA), and hit calling for pooled CRISPR screens including viability screens and drug resistance/sensitivity studies.

日本語の概要は準備中です。原文の説明を表示しています。

NGS analysis toolkit. Used for BAM to bigWig conversion, quality control (correlation, PCA, fingerprint plots), heatmaps/feature plots (TSS, peaks), suitable for ChIP-seq, RNA-seq, ATAC-seq visualization.

日本語の概要は準備中です。原文の説明を表示しています。

A low-level plotting library for comprehensive customization. Use when fine-grained control over every plot element is needed, creating new types of charts, or integrating into specific scientific workflows. Can export to PNG/PDF/SVG for publication. For quick statistical charts, use seaborn; for interactive charts, use plotly; for journal-style, publication-ready multi-panel charts, use scientific-visualization.

日本語の概要は準備中です。原文の説明を表示しています。

Generate meta-analysis forest plots for binary classification data. Input is a CSV file containing study names, event counts and sample sizes for experimental and control groups. Output includes forest plot PNG and data table CSV.

日本語の概要は準備中です。原文の説明を表示しています。

Conduct professional peer reviews for papers or theses, providing structured evaluations and improvement suggestions; use when you need a pre-submission assessment, an internal review, or academic quality control.

日本語の概要は準備中です。原文の説明を表示しています。

Designs a structured real-world evidence study using EHR, claims, or registry data, with explicit handling of time zero, eligibility windows, exposure definitions, outcome windows, censoring, confounding control, and target-trial-emulation logic. Use this skill when the user needs study-type design and protocol framing for an observational clinical study based on routine-care data. Do not invent database fields, follow-up completeness, linkage, coding validity, or causal identifiability.

日本語の概要は準備中です。原文の説明を表示しています。

Generates complete conventional non-oncology diagnostic machine-learning research designs from a user-provided disease context, optional mechanism theme, and validation direction. Use when a study centers on disease-vs-control transcriptome comparison, optional mechanism-gene restriction, feature shrinkage, diagnostic model construction, ROC / calibration / DCA evaluation, interpretation layers, and orthogonal validation. Covers five study patterns and always outputs Lite / Standard / Advanced / Publication+ with a recommended primary plan, stepwise workflow, figure plan, validation hierarchy, minimal executable version, publication upgrade path, and strictly verified literature retrieval.

日本語の概要は準備中です。原文の説明を表示しています。

Designs a realistic, execution-aware biomedical study version under explicit constraints of samples, time, budget, data access, lab capacity, team skill, and validation resources. Always use this skill when the user has a real study idea, a candidate route, or a partially framed project but cannot assume ideal conditions. If critical feasibility inputs are missing, first clarify what resources are currently available, what resources may be obtainable, and what resources are realistically unavailable. Do not invent access, capabilities, collaborations, or validation resources. Focus first on feasibility-constrained study framing, route narrowing, dependency control, and minimum viable study design.

日本語の概要は準備中です。原文の説明を表示しています。

Generates complete FAERS-style pharmacovigilance disproportionality research designs from a user-provided drug class, comparator strategy, adverse-event domain, and patient-group stratification. Always use this skill whenever a user wants to design, plan, or build a spontaneous-report safety signal study using FAERS or a similar pharmacovigilance database, especially when the article logic includes product selection, indication-group stratification, MedDRA-based adverse-event extraction, serious-case filtering, suspect-drug and concomitant-exclusion logic, reporting odds ratio analysis, comparator-drug benchmarking, cross-drug comparison, and cautious signal interpretation without causal overclaiming. Covers five study patterns (single-drug disproportionality workflow, multi-drug class comparison workflow, indication-stratified workflow, comparator-controlled signal screening workflow...

日本語の概要は準備中です。原文の説明を表示しています。

Generates complete Mendelian randomization study designs from a user-provided exposure and outcome direction. Always use this skill whenever a user wants to design, plan, or build a Mendelian randomization study — even if phrased as "help me write a paper on X", "design an MR study for Y", or "I want to test whether A causally affects B using GWAS". Covers core two-sample MR design, optional bidirectional follow-up, optional multivariable MR, IV selection logic, ancestry alignment, harmonization, IVW as the default primary estimator, weighted median / MR-Egger / MR-PRESSO / leave-one-out sensitivity analyses, Steiger directionality, heterogeneity / pleiotropy checks, and explicit claim-boundary control. Always outputs four workload configs (Lite / Standard / Advanced / Publication+) with a recommended primary plan, stepwise workflow, method rationale, validation ladder, figure plan, minimal executable version, and strictly verified literature guidance with no fabricated references.

日本語の概要は準備中です。原文の説明を表示しています。

Designs retrospective or prospective clinical cohort study protocols for biomedical and clinical research. Always use this skill when the user needs a cohort-based study plan rather than a general study idea, evidence summary, or mechanistic experiment design. Focus on cohort appropriateness, enrollment logic, baseline time-zero definition, follow-up structure, endpoint definition, variable collection, confounding control, and a coherent primary statistical analysis line. Do not invent data availability, follow-up completeness, outcome ascertainment quality, sample size adequacy, or causal interpretability.

日本語の概要は準備中です。原文の説明を表示しています。

Explains why studies on the same biomedical topic reach different or opposing conclusions by auditing differences in population, endpoint definition, sample source, assay or platform, study design, statistical model, adjustment strategy, validation chain, and bias control. It separates true contradiction from apparent contradiction caused by framing or methods. Never fabricate references, PMIDs, DOIs, trial identifiers, dataset details, platform details, study features, or conflict explanations that are not supported by the input.

日本語の概要は準備中です。原文の説明を表示しています。

Generates complete bidirectional multi-phenotype Mendelian randomization research designs from a user-provided exposure family and outcome family. Always use this skill whenever a user wants to design, plan, or build a genome-wide causal-inference study based on publicly available GWAS summary statistics, especially when the article logic includes multiple exposures, multiple outcomes or subtypes, bidirectional MR, IV filtering, IVW as the main estimator, weighted median / MR-Egger / MR-PRESSO sensitivity analyses, leave-one-out testing, heterogeneity / pleiotropy checks, and multiple-testing control with FDR. Covers five study patterns (single-family bidirectional MR, multi-phenotype screening MR, subtype-resolved MR, phenome-style bidirectional causal map, mechanism-prioritized MR follow-up) and always outputs four workload configs (Lite / Standard / Advanced / Publication+) with recommended primary plan, step-by-step workflow, figure plan, validation strategy, minimal executable version...

日本語の概要は準備中です。原文の説明を表示しています。

Assesses whether study results are trustworthy by auditing design integrity, sample structure, statistical handling, bias control, validation chain, and claim discipline. It identifies where results are robust, fragile, overfit, under-validated, or overclaimed. Always separate reported findings from reliability judgment. Never fabricate references, PMIDs, DOIs, trial identifiers, study features, or validation claims.

日本語の概要は準備中です。原文の説明を表示しています。

Use when evaluating diagnostic biomarker performance from case-control expression data with logistic regression and ROC curves, exporting coefficient and AUC tables together with a ROC PDF. NOT for: survival analysis, time-to-event outcomes, multiclass classification, calibration curves, decision-curve analysis, or nomogram construction.

日本語の概要は準備中です。原文の説明を表示しています。

Use when estimating immune infiltration from bulk RNA-seq expression matrices with ssGSEA/GSVA, comparing case versus control groups, and generating downstream immune-score visualizations. NOT for single-cell RNA-seq, absolute cell proportion estimation, or clinical decision making.

日本語の概要は準備中です。原文の説明を表示しています。

Generates complete FAERS pharmacovigilance study designs for multi-drug or class-level safety comparison inside one predefined SOC or AE family using active comparators, disproportionality analysis, subgroup characterization, and reviewer-facing evidence control.

日本語の概要は準備中です。原文の説明を表示しています。

Designs cell-based and animal-based validation plans that translate computational, omics, biomarker, genetic, or clinical findings into experimentally testable validation routes. Always use this skill whenever a user wants to move from an in silico, statistical, or clinical association finding toward wet-lab validation using cell systems, organoid-like systems, xenograft or genetically relevant animal models. It should define the exact claim to test, separate mechanism-testing from association-support and translational-support goals, choose the best-fit model family, specify perturbation strategy, readouts, controls, sequencing of experiments, and four workload configurations (Lite / Standard / Advanced / Publication+) with one recommended primary plan. Never fabricate model availability, reagent availability, species relevance, assay feasibility, phenotype penetrance, expected effect sizes, validation success, or literature references.

日本語の概要は準備中です。原文の説明を表示しています。

Use when building a weighted gene co-expression network from a bulk expression matrix and a sample group file, filtering variable genes by MAD, identifying co-expression modules with WGCNA, correlating modules with traits, and exporting module-level plots and gene tables. NOT for single-cell RNA-seq, differential expression testing, methylation analysis, or datasets that are too small for WGCNA after quality control.

日本語の概要は準備中です。原文の説明を表示しています。

Detects methodological gaps across study design, analysis, validation, bias control, reproducibility, and implementation readiness within a biomedical research area. Use this skill when a user wants to identify what current studies are still methodologically missing, which weaknesses are most consequential, and what upgrade path would produce a stronger next-step study. Always separate design gaps, analysis gaps, validation gaps, and reproducibility gaps. Never treat technical complexity as methodological rigor.

日本語の概要は準備中です。原文の説明を表示しています。

Use when selecting predictive genes or other molecular features from bulk expression matrices for binary case-vs-control classification with elastic net logistic regression, including coefficient path and cross-validation plots. Trigger keywords: elastic net, glmnet, feature selection, binary classification, lambda.min, lambda.1se. NOT for: survival/Cox modeling, multiclass outcomes, single-cell data, or non-expression tables.

日本語の概要は準備中です。原文の説明を表示しています。

Use when analyzing bulk RNA-seq or microarray expression data to identify differentially expressed genes between two biological groups (case vs control), with volcano plots and heatmap visualization. NOT for:single-cell RNA-seq, methylation analysis, non-expression data.

日本語の概要は準備中です。原文の説明を表示しています。

Use when estimating relative immune cell infiltration from a bulk expression matrix with a CIBERSORT-style nu-SVR deconvolution workflow based on an LM22 signature matrix, comparing one case group against one control group, and generating structured tables plus immune-fraction plots. NOT for single-cell RNA-seq, spatial data, clinical diagnosis, or workflows that require the original hosted CIBERSORT web service.

日本語の概要は準備中です。原文の説明を表示しています。